Return to Clinical Trials Search Results

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

To compare the efficacy of vepugratinib in combination with EV plus pembrolizumab versus placebo with EV plus pembrolizumab